Retavase Trademark Details

Retavase was registered on Tuesday, July 21, 1998 and is currently owned by Ekr Therapeutics, Inc. under the registration number 2175074 . This mark is alive with a status of Registered and Renewed. The last case file activity for this mark occured 15 years ago on Thursday, November 20, 2008, according to the United State Patent & Trademark Office
Word Mark Retavase
Status Alive Registered 800 — Registered and Renewed

Current Owner

Ekr Therapeutics, Inc. of Cedar Knolls, NJ

View all trademarks for Ekr Therapeutics, Inc.
Other Trademarks for Ekr Therapeutics, Inc.

Previous Owners

Boehringer Mannheim Corporation of Indianapolis, IN

View all trademarks for Boehringer Mannheim Corporation
Other Trademarks for Boehringer Mannheim Corporation

Pdl Biopharma, Inc. of Fremont, CA

View all trademarks for Pdl Biopharma, Inc.
Other Trademarks for Pdl Biopharma, Inc.

Centocor Incorporated of Malvern, PA

View all trademarks for Centocor Incorporated
Serial Number 75324869
Registration Number 2175074
Status Date Thursday, November 20, 2008
Filing Date Thursday, November 20, 2008
Registration Date Tuesday, July 21, 1998
Attorney Vanessa A. Ignacio, Esq.

Correspondent

Vanessa A. Ignacio, Esq.
Lowenstein Sandler PC
65 Livingston Avenue
Roseland NJ 07068

Case File Statements

Goods & Services Cardiovascular Agent, Namely, a Recombinant Plasminogen Activator Compound, for Use in the Management of Acute Myocardial Infarction

Classifications

International Class Codes
005 — Class 5 includes mainly pharmaceuticals and other preparations for medical or veterinary purposes.
U.S. Class Codes 006, 018, 044, 046, 051, 052
Status 6 — Active
Status Date Wednesday, August 6, 1997
First Use Anywhere Thursday, January 2, 1997
First Use In Commerce Thursday, January 2, 1997
Primary Code 005

You must be signed in to print.

Once signed in, look for the PDF button.